Metsera gains on early-stage results of weight loss drug

ReutersJun 9, 2025 12:55 PM

View all comments（0）



Shares of drug developer Metsera MTSR.O rise 17.28% to $32.24 premarket

Co says its experimental weight loss drug, MET-233i, hit up to 8.4% weight loss, on placebo adjusted basis, at 36 days in a small, early-stage trial

MET-233i, a long-acting injectable monthly amylin analogue, is being developed as a standalone treatment and in combination with another experimental GLP-1 drug MET-097i

The trial studied MET-233i in 80 participants with overweight or obesity without type 2 diabetes

Up to last close, stock up 3.7% since it went public in January

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Inflation 'High Fever' Fails to Stop Rally? BTC Temporarily Loses 80,000 Mark, But Arthur Hayes Sees Peak of $126,000

Higher-than-expected CPI data triggered a Bitcoin drop below $80,000, but the BitMEX co-founder remains staunchly bullish on BTC.

Japan and South Korea Stocks Open Lower, Samsung Strike Storm and Higher-Than-Expected Inflation Disrupt Markets

TradingKey - On May 13, the Nikkei 225 Index opened 0.5% lower, while South Korea’s KOSPI Index opened down 1.7% before losses further widened to 3%.

Today’s Market Recap: US Inflation Hits 3-Year Peak as Market Braces for Trump’s China Visit and Fed Leadership Shift

April inflation hit a three-year peak of 3.8%, pressuring the Nasdaq and tech stocks. Markets are further braced by Kevin Warsh’s Fed Chair confirmation, the maintenance of Trump’s 10% global tariffs, and a high-profile U.S. business delegation preparing for a strategic state visit to China.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools